lenvatinib

• 

Pembrolizumab plus lenvatinib for non-clear cell kidney cancer

By Sharon Deveson Kell|2023-10-02T08:53:12+00:002 Oct 2023|Drug treatments|

Immunotherapy combinations are becoming the standard treatment for people with [...]

Read More

Comments Off on Pembrolizumab plus lenvatinib for non-clear cell kidney cancer

• 

Pembrolizumab plus lenvatinib as first-line treatment for advanced non-clear cell kidney cancer

By Sharon Deveson Kell|2023-07-18T06:58:37+00:0018 Jul 2023|Drug treatments|

Immunotherapy combinations are becoming the standard treatment after surgery for [...]

Read More

Comments Off on Pembrolizumab plus lenvatinib as first-line treatment for advanced non-clear cell kidney cancer

• 

Four-year follow-up with lenvatinib plus pembrolizumab for advanced kidney cancer

By Sharon Deveson Kell|2023-06-12T08:21:24+00:007 Jun 2023|Drug treatments|

Further follow-up data from the phase 3 CLEAR study with [...]

Read More

Comments Off on Four-year follow-up with lenvatinib plus pembrolizumab for advanced kidney cancer

• 

Benefits persist for lenvatinib plus pembrolizumab in advanced kidney cancer

By Sharon Deveson Kell|2023-03-15T09:03:59+00:0015 Mar 2023|Drug treatments|

Lenvatinib plus pembrolizumab has already been shown to improve survival [...]

Read More

Comments Off on Benefits persist for lenvatinib plus pembrolizumab in advanced kidney cancer

• 

NICE approves pembrolizumab plus lenvatinib combination for advanced kidney cancer

By Sharon Deveson Kell|2022-11-30T15:29:22+00:0030 Nov 2022|Drug treatments|

The National Institute for Health and Care Excellence (NICE) has [...]

Read More

Comments Off on NICE approves pembrolizumab plus lenvatinib combination for advanced kidney cancer

• 

ESMO 2022: Pembrolizumab plus lenvatinib shows promise for non clear cell kidney cancer

By Sharon Deveson Kell|2022-10-25T07:38:41+00:0014 Sep 2022|Drug treatments|

The phase 2 KEYNOTE-B61 study was presented at the recent [...]

Read More

Comments Off on ESMO 2022: Pembrolizumab plus lenvatinib shows promise for non clear cell kidney cancer

• 

ESMO 2022: Update of the lenvatinib plus pembrolizumab versus sunitinib study in patients with advanced kidney cancer

By Sharon Deveson Kell|2022-09-14T08:02:43+00:0013 Sep 2022|Drug treatments|

Results from the phase 3 CLEAR studywere presented at the [...]

Read More

Comments Off on ESMO 2022: Update of the lenvatinib plus pembrolizumab versus sunitinib study in patients with advanced kidney cancer

• 

Health-related quality of life with lenvatinib in combination with everolimus

By Sharon Deveson Kell|2022-07-28T14:27:48+00:0028 Jul 2022|Drug treatments|

Maintaining good health-related quality of life is important for all [...]

Read More

Comments Off on Health-related quality of life with lenvatinib in combination with everolimus

• 

Quality of life on lenvatinib plus pembrolizumab combination

By Sharon Deveson Kell|2022-05-17T07:35:28+00:0017 May 2022|Drug treatments|

In this study, the health-related quality of life (HRQoL) of [...]

Read More

Comments Off on Quality of life on lenvatinib plus pembrolizumab combination

• 

Health-related quality of life for kidney cancer patients on pembrolizumab/lenvatinib

By Sharon Deveson Kell|2021-08-20T08:07:49+00:0020 Aug 2021|Drug treatments|

In this video, Dr Bradley McGregor from the Dana-Farber Cancer [...]

Read More

Comments Off on Health-related quality of life for kidney cancer patients on pembrolizumab/lenvatinib